TY  - JOUR
T1  - Immunotherapy in breast cancer
A1  - Nematollah Rostami
A1  - Zeinab Mazloumi
A1  - Fatemeh Aghamaleki
A1  - Sima Rad
A1  - Abolfazl Movafagh
A1  - Mojgan Sheikhpour
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2019
VL  - 8
IS  - 4
DO  - 10.4103/ccij.ccij_45_19
SP  - 139
EP  - 143
N2  - 
Over the last few years, the developments around cancer immunotherapy have led to a paradigm shift in the treatment of many different cancers and leukemias, in particular, melanoma, renal, bladder, and lung cancers with a remarkable impact on response rate and most importantly, overall survival was noticed. Breast cancer is most commonly considered to be a “noninflamed” cancer, and hence, this shift has been less marked within its treatment. However, some subsets of breast cancer, most notably triple-negative breast cancer, are deemed to be more “inflamed” and therefore may prove to be an appropriate cohort for immunotherapy.

UR  - https://ccij-online.org/article/immunotherapy-in-breast-cancer-800
ER  -